Literature DB >> 9106177

Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters.

L S Hofstra1, E G de Vries, C A Uyl-de Groot, E Vellenga.   

Abstract

Recombinant growth factors, particularly granulocyte-macrophage colony-stimulating factor (GM-CSF), have been only available for a few years. Since their introduction they have affected the management of drug-induced neutropenia, the use of dose intensive chemotherapy regimens and in the setting of autologous stem cell transplantation. This review addresses the clinical role of GM-CSF, using the data available, in neutrophil recovery in relation to various health care parameters.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9106177     DOI： 10.1007/bf02990845

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  64 in total

1.  Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection.

Authors:  G P Bodey; E Anaissie; J Gutterman; S Vadhan-Raj
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

2.  Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Authors:  E B Rubenstein; K Rolston; R S Benjamin; J Loewy; C Escalante; E Manzullo; P Hughes; B Moreland; A Fender; K Kennedy
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

3.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

Authors:  A D Elias; L Ayash; K C Anderson; M Hunt; C Wheeler; G Schwartz; I Tepler; R Mazanet; C Lynch; S Pap
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

4.  Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children.

Authors:  P Riikonen; U M Saarinen; A Mäkipernaa; L Hovi; A Komulainen; J Pihkala; H Jalanko
Journal:  Pediatr Infect Dis J       Date:  1994-03       Impact factor: 2.129

5.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.

Authors:  H H Gerhartz; M Engelhard; P Meusers; G Brittinger; W Wilmanns; G Schlimok; P Mueller; D Huhn; R Musch; W Siegert
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

6.  A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma.

Authors:  H Link; M A Boogaerts; A M Carella; A Ferrant; H Gadner; N C Gorin; I Harabacz; J L Harousseau; P Hervé; J Holldack
Journal:  Blood       Date:  1992-11-01       Impact factor: 22.113

7.  A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.

Authors:  E G de Vries; B Biesma; P H Willemse; N H Mulder; A C Stern; J G Aalders; E Vellenga
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

9.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

Authors:  J M Rowe; J W Andersen; J J Mazza; J M Bennett; E Paietta; F A Hayes; D Oette; P A Cassileth; E A Stadtmauer; P H Wiernik
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

10.  Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.

Authors:  J C Yau; J A Neidhart; P Triozzi; S Verma; J Nemunaitis; D P Quick; D G Mayernik; D H Oette; F A Haynes; J Holcenberg
Journal:  Am J Hematol       Date:  1996-04       Impact factor: 10.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.